What are the CD4 count thresholds, recommended drug regimens, and duration for Mycobacterium avium complex (MAC) and Pneumocystis jirovecii pneumonia (PJP) prophylaxis in HIV infection?

MAC and PJP Prophylaxis in HIV: CD4 Thresholds and Regimens

MAC (Mycobacterium avium complex) Prophylaxis

Initiate MAC prophylaxis when CD4 count falls below 50 cells/µL, using azithromycin 1200 mg once weekly as the preferred regimen. 1, 2

Primary Prophylaxis Initiation

• CD4 threshold: <50 cells/µL 1, 2
• Rule out active disseminated MAC disease by clinical assessment before starting prophylaxis, which may include blood culture if clinically indicated 1
• Exclude active tuberculosis before initiating rifabutin to prevent rifampin resistance 1, 2

Preferred Drug Regimens (in order of preference)

1. Azithromycin 1200 mg orally once weekly - preferred due to efficacy, ease of use, and lower risk of macrolide-resistant breakthrough compared to daily clarithromycin 1, 3
2. Clarithromycin 500 mg orally twice daily - alternative agent, requires twice-daily dosing with higher resistance risk 1
3. Rifabutin 300 mg orally daily - only when macrolides cannot be tolerated; less effective and has significant drug interactions with antiretrovirals 1, 2

Critical caveat: The combination of clarithromycin plus rifabutin is no more effective than clarithromycin alone and causes more adverse effects—do not use this combination 2

Discontinuing Primary Prophylaxis

• Stop prophylaxis when CD4 count rises to >100 cells/µL for ≥3 months on HAART with sustained viral suppression 4, 5, 1
• Restart prophylaxis if CD4 count decreases to <50-100 cells/µL 4, 1

Secondary Prophylaxis (After Treated MAC Disease)

• Continue lifelong treatment with clarithromycin 500 mg twice daily (never exceed this dose—1000 mg twice daily increases mortality) plus ethambutol 15 mg/kg daily, with or without rifabutin 1, 4, 5
• Can discontinue after ≥12 months of treatment if asymptomatic with CD4 >100 cells/µL sustained for ≥6 months on HAART 1
• Reinitiate if CD4 drops below 100 cells/µL 1

---

PJP (Pneumocystis jirovecii Pneumonia) Prophylaxis

Initiate PJP prophylaxis when CD4 count falls below 200 cells/µL or CD4 percentage <14%, using trimethoprim-sulfamethoxazole one double-strength tablet daily as first-line therapy.

Primary Prophylaxis Initiation

• CD4 count threshold: <200 cells/µL 5
• CD4 percentage threshold: <14% (even if absolute count >200) 5, 6
• Additional indication: History of oropharyngeal candidiasis regardless of CD4 count 5

Important pitfall: Providers often miss the CD4 percentage criterion—13% of patients have discordance between absolute count and percentage, and those with count >200 but percentage <14% are significantly undertreated 6

Preferred Drug Regimens (in order of preference)

1. Trimethoprim-sulfamethoxazole (TMP-SMX) one double-strength tablet (160/800 mg) daily - most effective, also provides protection against toxoplasmosis and bacterial infections 5, 7
   • Alternative dosing: One double-strength tablet three times weekly or one single-strength tablet daily 7
2. Dapsone 100 mg orally daily - for TMP-SMX intolerance 7
3. Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer - for patients ≥5 years old who cannot tolerate oral agents 7
4. Atovaquone 1500 mg orally daily - alternative option 5

Discontinuing Primary Prophylaxis

• Stop when CD4 count rises to >200 cells/µL for ≥3 months on suppressive antiretroviral therapy 4
• Restart prophylaxis if CD4 decreases to <200 cells/µL or <14% 4

Secondary Prophylaxis (After Treated PJP)

• Continue lifelong prophylaxis with same regimens as primary prophylaxis 7
• Can safely discontinue if CD4 >100 cells/µL with suppressed viral load (<400 copies/mL) sustained for ≥6 months—incidence of recurrence is only 3.9 per 1000 person-years in this scenario 8
• Reinitiate if CD4 drops below 100-200 cells/µL 8

Pediatric Considerations

MAC: Age-adjusted CD4 thresholds differ significantly from adults 4, 5:

• Age ≥6 years: <50 cells/µL
• Age 2-6 years: <75 cells/µL
• Age 1-2 years: <500 cells/µL
• Age <12 months: <750 cells/µL

PJP: Monitor CD4 counts every 1-6 months depending on proximity to threshold; use TMP-SMX 150 mg/m² divided three times weekly as preferred regimen 7

Drug Interactions

• Rifabutin cannot be used with certain protease inhibitors and requires dose adjustments with others due to CYP450 interactions 1
• Clarithromycin levels increase with protease inhibitors but decrease with efavirenz; azithromycin has no CYP450 interactions and is safer with antiretrovirals 5